Congress orders FDA to study hair straighteners and cancer risk in women of color
S. 2285 — Uterine Cancer Study Act of 2025 · Filed by Lisa Blunt Rochester (D-DE) · 2 cosponsors · Introduced Jul 15, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill directs the Secretary of Health and Human Services, working with the FDA and National Institutes of Health, to conduct a two-year study on whether chemical hair straighteners increase uterine cancer risk, with special attention to higher rates among women of color. The study will examine existing research, analyze whether different product formulations (dyes, bleach, perms) carry different risks, and determine if the FDA should require additional safety testing before these products reach consumers.
Why we flagged it
The bill's sole function is to authorize and structure a government study into a potential consumer product safety issue. It is a straightforward research directive with no hidden mechanisms or narrow beneficiaries.
What the text implies
- Study results may trigger FDA regulatory action (additional testing, labeling, or restrictions) on hair straightener manufacturers, potentially increasing product development costs and market friction.
- Disaggregation by product type (dyes, bleach, perms) may reveal that certain formulations carry higher risk, creating market segmentation and competitive advantage for manufacturers of 'safer' variants.
- Two-year timeline means regulatory outcomes will not be visible until 2027, creating uncertainty for manufacturers and investors in the interim.
Who it affects
The bill funds public health research into a potential consumer safety hazard that may disproportionately affect women of color. It creates transparency and evidence-based regulatory guidance without imposing immediate costs on consumers or manufacturers—only requiring the FDA to study whether stronger safety standards are warranted.
Who stands to gain
- Hair care product manufacturers (potential regulatory clarity or competitive advantage for 'safer' f
- Research institutions and contract research organizations (study funding and execution)
Named in the bill
Secretary of Health and Human Services (HHS), Food and Drug Administration (FDA), National Institutes of Health (NIH), Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce, Hair straightener manufacturers (unnamed, but regulated sector)
Where it stands
2 cosponsors: 2 Democrats.
- Jul 15, 2025 — Introduced · Congress.gov: “Introduced in Senate”
- Jul 15, 2025 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
How this was measured
Analysis — Quorum's AI read the full bill text on Jun 8, 2026; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
As of — page rendered 2026-10-20.
“Congress orders FDA to study hair straighteners and cancer risk in women of color” QuorumCivic. https://share.quorumcivic.app/bill/119/s2285 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.